PEN
NYSEPenumbra, Inc
Technology · Surgical & Medical Instruments & Apparatus
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$747.6M
2021
$847.1M
2022
$1.1B
2023
$1.2B
2024
$1.4B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$1.4B
Net Income$177.7M
Gross Profit$942.4M
Oper Income$189.2M
EPS (dil)$4.52
Rev/sh$35.69
FCF/sh$4.45
Book/sh$36.30
Gross M67.1%
Oper M13.5%
Profit M12.7%
FCF M12.5%
ROE12.4%
ROA9.7%
ROIC13.2%
R&D/Rev2.6%
Rev Y/Y17.5%
Rev 3Y CAGR18.3%
EPS Y/Y1155.6%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+0.1%
Current Ratio6.64
Quick Ratio4.29
Debt/Eq—
Int Coverage144.3×
Net Debt—
Total Debt—
Cash & Eq$186.9M
Total Assets$1.8B
Oper CF$238.7M
Capex$63.7M
Free CF$174.9M
Buybacks$0
Equity$1.4B
Liabilities$398.9M
Shs Outstand0.04B
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $747.6M | $847.1M | $1.1B | $1.2B | $1.4B |
| Gross Profit | $475.4M | $535.2M | $682.6M | $755.0M | $942.4M |
| Operating Income | $-7.5M | $6.1M | $73.6M | $9.3M | $189.2M |
| Net Income | $2.6M | $-2.0M | $91.0M | $14.0M | $177.7M |
| Diluted EPS | $0.14 | $-0.05 | $2.32 | $0.36 | $4.52 |
| Operating Cash Flow | $9.5M | $-55.7M | $97.3M | $168.5M | $238.7M |
| Free Cash Flow | $-11.7M | $-75.0M | $82.1M | $147.3M | $174.9M |
COMMUNITY · $PEN0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.